nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—ABCC10—Cytarabine—lymphatic system cancer	0.24	0.331	CbGbCtD
Methotrexate—ABCC10—Vincristine—lymphatic system cancer	0.114	0.157	CbGbCtD
Methotrexate—ABCC3—Vincristine—lymphatic system cancer	0.0715	0.0988	CbGbCtD
Methotrexate—ABCC1—Mitoxantrone—lymphatic system cancer	0.0638	0.0881	CbGbCtD
Methotrexate—ABCG2—Teniposide—lymphatic system cancer	0.061	0.0843	CbGbCtD
Methotrexate—ABCC1—Vincristine—lymphatic system cancer	0.0439	0.0606	CbGbCtD
Methotrexate—ABCG2—Mitoxantrone—lymphatic system cancer	0.0427	0.059	CbGbCtD
Methotrexate—ABCC2—Vincristine—lymphatic system cancer	0.0325	0.0449	CbGbCtD
Methotrexate—ABCG2—Vincristine—lymphatic system cancer	0.0294	0.0406	CbGbCtD
Methotrexate—ABCB1—Mitoxantrone—lymphatic system cancer	0.0154	0.0213	CbGbCtD
Methotrexate—ABCB1—Vincristine—lymphatic system cancer	0.0106	0.0146	CbGbCtD
Methotrexate—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.00155	0.4	CbGdCrCtD
Methotrexate—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000923	0.238	CbGdCrCtD
Methotrexate—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000635	0.164	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	0.000394	0.102	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	0.000372	0.096	CbGdCrCtD
Methotrexate—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000319	0.00117	CcSEcCtD
Methotrexate—Malaise—Fludarabine—lymphatic system cancer	0.000316	0.00116	CcSEcCtD
Methotrexate—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000315	0.00116	CcSEcCtD
Methotrexate—Leukopenia—Fludarabine—lymphatic system cancer	0.000314	0.00115	CcSEcCtD
Methotrexate—Haematuria—Bleomycin—lymphatic system cancer	0.000314	0.00115	CcSEcCtD
Methotrexate—Pruritus—Mechlorethamine—lymphatic system cancer	0.000313	0.00115	CcSEcCtD
Methotrexate—Anorexia—Teniposide—lymphatic system cancer	0.000311	0.00114	CcSEcCtD
Methotrexate—Cough—Fludarabine—lymphatic system cancer	0.000306	0.00113	CcSEcCtD
Methotrexate—Pancytopenia—Carmustine—lymphatic system cancer	0.000306	0.00113	CcSEcCtD
Methotrexate—Hypotension—Teniposide—lymphatic system cancer	0.000304	0.00112	CcSEcCtD
Methotrexate—Convulsion—Fludarabine—lymphatic system cancer	0.000304	0.00112	CcSEcCtD
Methotrexate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000302	0.00111	CcSEcCtD
Methotrexate—Neutropenia—Carmustine—lymphatic system cancer	0.000301	0.00111	CcSEcCtD
Methotrexate—Myalgia—Fludarabine—lymphatic system cancer	0.000299	0.0011	CcSEcCtD
Methotrexate—Arthralgia—Fludarabine—lymphatic system cancer	0.000299	0.0011	CcSEcCtD
Methotrexate—Haemoglobin—Bleomycin—lymphatic system cancer	0.000297	0.00109	CcSEcCtD
Methotrexate—Haemorrhage—Bleomycin—lymphatic system cancer	0.000296	0.00109	CcSEcCtD
Methotrexate—Discomfort—Fludarabine—lymphatic system cancer	0.000295	0.00109	CcSEcCtD
Methotrexate—Pancytopenia—Vincristine—lymphatic system cancer	0.000292	0.00107	CcSEcCtD
Methotrexate—Dyspnoea—Teniposide—lymphatic system cancer	0.000291	0.00107	CcSEcCtD
Methotrexate—Pneumonia—Carmustine—lymphatic system cancer	0.000289	0.00106	CcSEcCtD
Methotrexate—Confusional state—Fludarabine—lymphatic system cancer	0.000289	0.00106	CcSEcCtD
Methotrexate—Dysuria—Vincristine—lymphatic system cancer	0.000288	0.00106	CcSEcCtD
Methotrexate—Neutropenia—Vincristine—lymphatic system cancer	0.000288	0.00106	CcSEcCtD
Methotrexate—Depression—Carmustine—lymphatic system cancer	0.000287	0.00105	CcSEcCtD
Methotrexate—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000286	0.00105	CcSEcCtD
Methotrexate—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000285	0.00105	CcSEcCtD
Methotrexate—Infection—Fludarabine—lymphatic system cancer	0.000285	0.00105	CcSEcCtD
Methotrexate—Erectile dysfunction—Vincristine—lymphatic system cancer	0.000283	0.00104	CcSEcCtD
Methotrexate—Decreased appetite—Teniposide—lymphatic system cancer	0.000283	0.00104	CcSEcCtD
Methotrexate—Renal failure—Carmustine—lymphatic system cancer	0.000282	0.00104	CcSEcCtD
Methotrexate—Vomiting—Mechlorethamine—lymphatic system cancer	0.000281	0.00103	CcSEcCtD
Methotrexate—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000281	0.00103	CcSEcCtD
Methotrexate—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000281	0.00103	CcSEcCtD
Methotrexate—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00028	0.00103	CcSEcCtD
Methotrexate—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00028	0.00103	CcSEcCtD
Methotrexate—Stomatitis—Carmustine—lymphatic system cancer	0.00028	0.00103	CcSEcCtD
Methotrexate—Rash—Mechlorethamine—lymphatic system cancer	0.000279	0.00102	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000278	0.00102	CcSEcCtD
Methotrexate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000278	0.00102	CcSEcCtD
Methotrexate—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000277	0.00102	CcSEcCtD
Methotrexate—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000276	0.00101	CcSEcCtD
Methotrexate—Pneumonia—Vincristine—lymphatic system cancer	0.000276	0.00101	CcSEcCtD
Methotrexate—Depression—Vincristine—lymphatic system cancer	0.000274	0.00101	CcSEcCtD
Methotrexate—Anorexia—Fludarabine—lymphatic system cancer	0.000273	0.001	CcSEcCtD
Methotrexate—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000269	0.000988	CcSEcCtD
Methotrexate—Feeling abnormal—Teniposide—lymphatic system cancer	0.000269	0.000987	CcSEcCtD
Methotrexate—Stomatitis—Vincristine—lymphatic system cancer	0.000267	0.000983	CcSEcCtD
Methotrexate—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000267	0.000982	CcSEcCtD
Methotrexate—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000266	0.00098	CcSEcCtD
Methotrexate—Chills—Bleomycin—lymphatic system cancer	0.000265	0.000975	CcSEcCtD
Methotrexate—Sweating—Vincristine—lymphatic system cancer	0.000263	0.000967	CcSEcCtD
Methotrexate—Renal failure—Mitoxantrone—lymphatic system cancer	0.000263	0.000966	CcSEcCtD
Methotrexate—Nausea—Mechlorethamine—lymphatic system cancer	0.000263	0.000965	CcSEcCtD
Methotrexate—Alopecia—Bleomycin—lymphatic system cancer	0.000261	0.00096	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000261	0.000959	CcSEcCtD
Methotrexate—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00026	0.000957	CcSEcCtD
Methotrexate—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00026	0.000955	CcSEcCtD
Methotrexate—Haemoglobin—Carmustine—lymphatic system cancer	0.000259	0.000953	CcSEcCtD
Methotrexate—Urticaria—Teniposide—lymphatic system cancer	0.000259	0.000952	CcSEcCtD
Methotrexate—Haemorrhage—Carmustine—lymphatic system cancer	0.000258	0.000948	CcSEcCtD
Methotrexate—Body temperature increased—Teniposide—lymphatic system cancer	0.000258	0.000947	CcSEcCtD
Methotrexate—Abdominal pain—Teniposide—lymphatic system cancer	0.000258	0.000947	CcSEcCtD
Methotrexate—Erythema—Bleomycin—lymphatic system cancer	0.000257	0.000946	CcSEcCtD
Methotrexate—Paraesthesia—Fludarabine—lymphatic system cancer	0.000257	0.000945	CcSEcCtD
Methotrexate—Sweating—Mitoxantrone—lymphatic system cancer	0.000256	0.000942	CcSEcCtD
Methotrexate—Dyspnoea—Fludarabine—lymphatic system cancer	0.000255	0.000939	CcSEcCtD
Methotrexate—Haematuria—Mitoxantrone—lymphatic system cancer	0.000255	0.000937	CcSEcCtD
Methotrexate—Dyspepsia—Fludarabine—lymphatic system cancer	0.000252	0.000927	CcSEcCtD
Methotrexate—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000249	0.000917	CcSEcCtD
Methotrexate—Decreased appetite—Fludarabine—lymphatic system cancer	0.000249	0.000915	CcSEcCtD
Methotrexate—Visual impairment—Carmustine—lymphatic system cancer	0.000249	0.000914	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000247	0.000909	CcSEcCtD
Methotrexate—Fatigue—Fludarabine—lymphatic system cancer	0.000247	0.000908	CcSEcCtD
Methotrexate—Pain—Fludarabine—lymphatic system cancer	0.000245	0.0009	CcSEcCtD
Methotrexate—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000243	0.000894	CcSEcCtD
Methotrexate—Urethral disorder—Vincristine—lymphatic system cancer	0.000241	0.000888	CcSEcCtD
Methotrexate—Eye disorder—Carmustine—lymphatic system cancer	0.000241	0.000886	CcSEcCtD
Methotrexate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000241	0.000886	CcSEcCtD
Methotrexate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00024	0.000883	CcSEcCtD
Methotrexate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00024	0.000882	CcSEcCtD
Methotrexate—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00024	0.000882	CcSEcCtD
Methotrexate—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000239	0.000878	CcSEcCtD
Methotrexate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000238	0.000875	CcSEcCtD
Methotrexate—Anaemia—Bleomycin—lymphatic system cancer	0.000238	0.000874	CcSEcCtD
Methotrexate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000236	0.000868	CcSEcCtD
Methotrexate—Asthenia—Teniposide—lymphatic system cancer	0.000234	0.00086	CcSEcCtD
Methotrexate—Malaise—Bleomycin—lymphatic system cancer	0.000232	0.000853	CcSEcCtD
Methotrexate—Pruritus—Teniposide—lymphatic system cancer	0.000231	0.000848	CcSEcCtD
Methotrexate—Leukopenia—Bleomycin—lymphatic system cancer	0.00023	0.000847	CcSEcCtD
Methotrexate—Cardiac disorder—Vincristine—lymphatic system cancer	0.000229	0.00084	CcSEcCtD
Methotrexate—Alopecia—Carmustine—lymphatic system cancer	0.000228	0.000838	CcSEcCtD
Methotrexate—Body temperature increased—Fludarabine—lymphatic system cancer	0.000226	0.000832	CcSEcCtD
Methotrexate—Mental disorder—Carmustine—lymphatic system cancer	0.000226	0.000831	CcSEcCtD
Methotrexate—Malnutrition—Carmustine—lymphatic system cancer	0.000225	0.000826	CcSEcCtD
Methotrexate—Erythema—Carmustine—lymphatic system cancer	0.000225	0.000826	CcSEcCtD
Methotrexate—Cough—Bleomycin—lymphatic system cancer	0.000225	0.000825	CcSEcCtD
Methotrexate—Angiopathy—Vincristine—lymphatic system cancer	0.000223	0.000821	CcSEcCtD
Methotrexate—Diarrhoea—Teniposide—lymphatic system cancer	0.000223	0.00082	CcSEcCtD
Methotrexate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000222	0.000816	CcSEcCtD
Methotrexate—Chest pain—Bleomycin—lymphatic system cancer	0.000219	0.000805	CcSEcCtD
Methotrexate—Myalgia—Bleomycin—lymphatic system cancer	0.000219	0.000805	CcSEcCtD
Methotrexate—Alopecia—Vincristine—lymphatic system cancer	0.000218	0.0008	CcSEcCtD
Methotrexate—Back pain—Carmustine—lymphatic system cancer	0.000217	0.000799	CcSEcCtD
Methotrexate—Discomfort—Bleomycin—lymphatic system cancer	0.000216	0.000796	CcSEcCtD
Methotrexate—Mental disorder—Vincristine—lymphatic system cancer	0.000216	0.000793	CcSEcCtD
Methotrexate—Chills—Mitoxantrone—lymphatic system cancer	0.000215	0.000791	CcSEcCtD
Methotrexate—Alopecia—Mitoxantrone—lymphatic system cancer	0.000212	0.000779	CcSEcCtD
Methotrexate—Confusional state—Bleomycin—lymphatic system cancer	0.000212	0.000778	CcSEcCtD
Methotrexate—Vision blurred—Carmustine—lymphatic system cancer	0.000212	0.000778	CcSEcCtD
Methotrexate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000211	0.000776	CcSEcCtD
Methotrexate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00021	0.000772	CcSEcCtD
Methotrexate—Erythema—Mitoxantrone—lymphatic system cancer	0.000209	0.000768	CcSEcCtD
Methotrexate—Infection—Bleomycin—lymphatic system cancer	0.000209	0.000767	CcSEcCtD
Methotrexate—Anaemia—Carmustine—lymphatic system cancer	0.000208	0.000763	CcSEcCtD
Methotrexate—Back pain—Vincristine—lymphatic system cancer	0.000207	0.000762	CcSEcCtD
Methotrexate—Vomiting—Teniposide—lymphatic system cancer	0.000207	0.000762	CcSEcCtD
Methotrexate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000206	0.000756	CcSEcCtD
Methotrexate—Asthenia—Fludarabine—lymphatic system cancer	0.000205	0.000755	CcSEcCtD
Methotrexate—Rash—Teniposide—lymphatic system cancer	0.000205	0.000755	CcSEcCtD
Methotrexate—Dermatitis—Teniposide—lymphatic system cancer	0.000205	0.000755	CcSEcCtD
Methotrexate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000204	0.000752	CcSEcCtD
Methotrexate—Headache—Teniposide—lymphatic system cancer	0.000204	0.00075	CcSEcCtD
Methotrexate—Pruritus—Fludarabine—lymphatic system cancer	0.000203	0.000745	CcSEcCtD
Methotrexate—Back pain—Mitoxantrone—lymphatic system cancer	0.000202	0.000742	CcSEcCtD
Methotrexate—Leukopenia—Carmustine—lymphatic system cancer	0.000201	0.000739	CcSEcCtD
Methotrexate—Anorexia—Bleomycin—lymphatic system cancer	0.0002	0.000736	CcSEcCtD
Methotrexate—Anaemia—Vincristine—lymphatic system cancer	0.000198	0.000728	CcSEcCtD
Methotrexate—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000197	0.000723	CcSEcCtD
Methotrexate—Hypotension—Bleomycin—lymphatic system cancer	0.000196	0.000721	CcSEcCtD
Methotrexate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000196	0.00072	CcSEcCtD
Methotrexate—Convulsion—Carmustine—lymphatic system cancer	0.000195	0.000715	CcSEcCtD
Methotrexate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000194	0.000712	CcSEcCtD
Methotrexate—Nausea—Teniposide—lymphatic system cancer	0.000194	0.000712	CcSEcCtD
Methotrexate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000193	0.000709	CcSEcCtD
Methotrexate—Vertigo—Vincristine—lymphatic system cancer	0.000193	0.000708	CcSEcCtD
Methotrexate—Leukopenia—Vincristine—lymphatic system cancer	0.000192	0.000705	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000191	0.000703	CcSEcCtD
Methotrexate—Myalgia—Carmustine—lymphatic system cancer	0.000191	0.000703	CcSEcCtD
Methotrexate—Chest pain—Carmustine—lymphatic system cancer	0.000191	0.000703	CcSEcCtD
Methotrexate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000189	0.000693	CcSEcCtD
Methotrexate—Malaise—Mitoxantrone—lymphatic system cancer	0.000188	0.000692	CcSEcCtD
Methotrexate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000187	0.000688	CcSEcCtD
Methotrexate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000187	0.000687	CcSEcCtD
Methotrexate—Convulsion—Vincristine—lymphatic system cancer	0.000186	0.000683	CcSEcCtD
Methotrexate—Confusional state—Carmustine—lymphatic system cancer	0.000185	0.000679	CcSEcCtD
Methotrexate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000183	0.000671	CcSEcCtD
Methotrexate—Myalgia—Vincristine—lymphatic system cancer	0.000183	0.000671	CcSEcCtD
Methotrexate—Cough—Mitoxantrone—lymphatic system cancer	0.000182	0.00067	CcSEcCtD
Methotrexate—Infection—Carmustine—lymphatic system cancer	0.000182	0.000669	CcSEcCtD
Methotrexate—Vomiting—Fludarabine—lymphatic system cancer	0.000182	0.000669	CcSEcCtD
Methotrexate—Convulsion—Mitoxantrone—lymphatic system cancer	0.000181	0.000665	CcSEcCtD
Methotrexate—Rash—Fludarabine—lymphatic system cancer	0.000181	0.000664	CcSEcCtD
Methotrexate—Dermatitis—Fludarabine—lymphatic system cancer	0.00018	0.000663	CcSEcCtD
Methotrexate—Pain—Bleomycin—lymphatic system cancer	0.00018	0.00066	CcSEcCtD
Methotrexate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000179	0.00066	CcSEcCtD
Methotrexate—Headache—Fludarabine—lymphatic system cancer	0.000179	0.00066	CcSEcCtD
Methotrexate—Chest pain—Mitoxantrone—lymphatic system cancer	0.000178	0.000653	CcSEcCtD
Methotrexate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000178	0.000653	CcSEcCtD
Methotrexate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000178	0.000653	CcSEcCtD
Methotrexate—Discomfort—Mitoxantrone—lymphatic system cancer	0.000176	0.000646	CcSEcCtD
Methotrexate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000175	0.000643	CcSEcCtD
Methotrexate—Anorexia—Carmustine—lymphatic system cancer	0.000175	0.000642	CcSEcCtD
Methotrexate—Infection—Vincristine—lymphatic system cancer	0.000174	0.000639	CcSEcCtD
Methotrexate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000173	0.000636	CcSEcCtD
Methotrexate—Confusional state—Mitoxantrone—lymphatic system cancer	0.000172	0.000632	CcSEcCtD
Methotrexate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000172	0.000631	CcSEcCtD
Methotrexate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000171	0.00063	CcSEcCtD
Methotrexate—Hypotension—Carmustine—lymphatic system cancer	0.000171	0.00063	CcSEcCtD
Methotrexate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00017	0.000626	CcSEcCtD
Methotrexate—Nausea—Fludarabine—lymphatic system cancer	0.00017	0.000625	CcSEcCtD
Methotrexate—Infection—Mitoxantrone—lymphatic system cancer	0.000169	0.000622	CcSEcCtD
Methotrexate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000169	0.000622	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000167	0.000614	CcSEcCtD
Methotrexate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000167	0.000613	CcSEcCtD
Methotrexate—Urticaria—Bleomycin—lymphatic system cancer	0.000167	0.000613	CcSEcCtD
Methotrexate—Anorexia—Vincristine—lymphatic system cancer	0.000167	0.000613	CcSEcCtD
Methotrexate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000166	0.00061	CcSEcCtD
Methotrexate—Insomnia—Carmustine—lymphatic system cancer	0.000166	0.000609	CcSEcCtD
Methotrexate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000166	0.000608	CcSEcCtD
Methotrexate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000165	0.000606	CcSEcCtD
Methotrexate—Paraesthesia—Carmustine—lymphatic system cancer	0.000165	0.000605	CcSEcCtD
Methotrexate—Hypotension—Vincristine—lymphatic system cancer	0.000163	0.000601	CcSEcCtD
Methotrexate—Dyspnoea—Carmustine—lymphatic system cancer	0.000163	0.000601	CcSEcCtD
Methotrexate—Somnolence—Carmustine—lymphatic system cancer	0.000163	0.000599	CcSEcCtD
Methotrexate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000162	0.000597	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000159	0.000586	CcSEcCtD
Methotrexate—Decreased appetite—Carmustine—lymphatic system cancer	0.000159	0.000586	CcSEcCtD
Methotrexate—Hypotension—Mitoxantrone—lymphatic system cancer	0.000159	0.000585	CcSEcCtD
Methotrexate—Insomnia—Vincristine—lymphatic system cancer	0.000158	0.000582	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000158	0.000582	CcSEcCtD
Methotrexate—Paraesthesia—Vincristine—lymphatic system cancer	0.000157	0.000578	CcSEcCtD
Methotrexate—Pain—Carmustine—lymphatic system cancer	0.000157	0.000576	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000155	0.000571	CcSEcCtD
Methotrexate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000155	0.000569	CcSEcCtD
Methotrexate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000153	0.000563	CcSEcCtD
Methotrexate—Decreased appetite—Vincristine—lymphatic system cancer	0.000152	0.000559	CcSEcCtD
Methotrexate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000152	0.000558	CcSEcCtD
Methotrexate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000151	0.000557	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Methotrexate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Methotrexate—Fatigue—Vincristine—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Methotrexate—Asthenia—Bleomycin—lymphatic system cancer	0.000151	0.000554	CcSEcCtD
Methotrexate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00015	0.000551	CcSEcCtD
Methotrexate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00015	0.000551	CcSEcCtD
Methotrexate—Pain—Vincristine—lymphatic system cancer	0.00015	0.00055	CcSEcCtD
Methotrexate—Pruritus—Bleomycin—lymphatic system cancer	0.000149	0.000546	CcSEcCtD
Methotrexate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000148	0.000545	CcSEcCtD
Methotrexate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000147	0.00054	CcSEcCtD
Methotrexate—Pain—Mitoxantrone—lymphatic system cancer	0.000146	0.000536	CcSEcCtD
Methotrexate—Abdominal pain—Carmustine—lymphatic system cancer	0.000145	0.000533	CcSEcCtD
Methotrexate—Body temperature increased—Carmustine—lymphatic system cancer	0.000145	0.000533	CcSEcCtD
Methotrexate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000143	0.000526	CcSEcCtD
Methotrexate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00014	0.000516	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000139	0.000512	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—lymphatic system cancer	0.000138	0.000508	CcSEcCtD
Methotrexate—Body temperature increased—Vincristine—lymphatic system cancer	0.000138	0.000508	CcSEcCtD
Methotrexate—Urticaria—Mitoxantrone—lymphatic system cancer	0.000135	0.000498	CcSEcCtD
Methotrexate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000135	0.000496	CcSEcCtD
Methotrexate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000135	0.000495	CcSEcCtD
Methotrexate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000135	0.000495	CcSEcCtD
Methotrexate—Vomiting—Bleomycin—lymphatic system cancer	0.000134	0.000491	CcSEcCtD
Methotrexate—Rash—Bleomycin—lymphatic system cancer	0.000132	0.000487	CcSEcCtD
Methotrexate—Dermatitis—Bleomycin—lymphatic system cancer	0.000132	0.000486	CcSEcCtD
Methotrexate—Asthenia—Carmustine—lymphatic system cancer	0.000132	0.000483	CcSEcCtD
Methotrexate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000129	0.000474	CcSEcCtD
Methotrexate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000126	0.000462	CcSEcCtD
Methotrexate—Asthenia—Vincristine—lymphatic system cancer	0.000126	0.000462	CcSEcCtD
Methotrexate—Diarrhoea—Carmustine—lymphatic system cancer	0.000125	0.000461	CcSEcCtD
Methotrexate—Nausea—Bleomycin—lymphatic system cancer	0.000125	0.000459	CcSEcCtD
Methotrexate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000122	0.000449	CcSEcCtD
Methotrexate—Dizziness—Carmustine—lymphatic system cancer	0.000121	0.000446	CcSEcCtD
Methotrexate—Diarrhoea—Vincristine—lymphatic system cancer	0.00012	0.00044	CcSEcCtD
Methotrexate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000117	0.000429	CcSEcCtD
Methotrexate—Vomiting—Carmustine—lymphatic system cancer	0.000117	0.000428	CcSEcCtD
Methotrexate—Dizziness—Vincristine—lymphatic system cancer	0.000116	0.000425	CcSEcCtD
Methotrexate—Rash—Carmustine—lymphatic system cancer	0.000116	0.000425	CcSEcCtD
Methotrexate—Dermatitis—Carmustine—lymphatic system cancer	0.000115	0.000424	CcSEcCtD
Methotrexate—Headache—Carmustine—lymphatic system cancer	0.000115	0.000422	CcSEcCtD
Methotrexate—Vomiting—Vincristine—lymphatic system cancer	0.000111	0.000409	CcSEcCtD
Methotrexate—Rash—Vincristine—lymphatic system cancer	0.00011	0.000406	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—lymphatic system cancer	0.00011	0.000405	CcSEcCtD
Methotrexate—Headache—Vincristine—lymphatic system cancer	0.00011	0.000403	CcSEcCtD
Methotrexate—Nausea—Carmustine—lymphatic system cancer	0.000109	0.0004	CcSEcCtD
Methotrexate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000108	0.000398	CcSEcCtD
Methotrexate—Rash—Mitoxantrone—lymphatic system cancer	0.000107	0.000395	CcSEcCtD
Methotrexate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000107	0.000395	CcSEcCtD
Methotrexate—Headache—Mitoxantrone—lymphatic system cancer	0.000107	0.000392	CcSEcCtD
Methotrexate—Nausea—Vincristine—lymphatic system cancer	0.000104	0.000382	CcSEcCtD
Methotrexate—Nausea—Mitoxantrone—lymphatic system cancer	0.000101	0.000372	CcSEcCtD
